Restructuring paved the way to growth

Article Excerpt

BAXTER INTERNATIONAL INC. $57 (New York symbol BAX; Conservative Growth Portfolio, Manufacturing & Industry sector; Shares outstanding: 651.5 million; Market cap: $37.1 billion; WSSF Rating: Average) operates in three areas of the biotechnology industry. Its Bioscience division makes equipment and drugs for treatment of hemophilia (40% of revenue). It also makes intravenous drug delivery equipment (40%), and dialysis equipment for kidney disease patients (20%). International markets account for roughly half of its sales. We generally recommend investors avoid pharmaceutical companies, due to the huge costs and risks of developing new drugs. But Baxter is different. Business mix cuts risk The company gets over half of its revenue and profit from medical devices and supplies. Hospitals and clinics must constantly replenish these items, which cuts Baxter’s risk. The company is also the leader in many of its markets, so customers are reluctant to switch to new suppliers. Baxter’s profits fell from $1.92 a share (total $1.2 billion) in 2002 to $1.52 a share ($922.0 million)…